GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MannKind Corp (STU:NNFN) » Definitions » Other Operating Expense

MannKind (STU:NNFN) Other Operating Expense : €0.0 Mil (TTM As of Sep. 2024)


View and export this data going back to . Start your Free Trial

What is MannKind Other Operating Expense?

MannKind's Other Operating Expense for the three months ended in Sep. 2024 was €0.0 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Sep. 2024 was €0.0 Mil.

MannKind's quarterly Other Operating Expense increased from Mar. 2024 (€-0.0 Mil) to Jun. 2024 (€0.0 Mil) but then stayed the same from Jun. 2024 (€0.0 Mil) to Sep. 2024 (€0.0 Mil).

MannKind's annual Other Operating Expense declined from Dec. 2021 (€0.3 Mil) to Dec. 2022 (€-0.0 Mil) and declined from Dec. 2022 (€-0.0 Mil) to Dec. 2023 (€-0.0 Mil).


MannKind Other Operating Expense Historical Data

The historical data trend for MannKind's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MannKind Other Operating Expense Chart

MannKind Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.30 - -

MannKind Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

MannKind Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MannKind Other Operating Expense Related Terms

Thank you for viewing the detailed overview of MannKind's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


MannKind Business Description

Traded in Other Exchanges
Address
1 Casper Street, Danbury, CT, USA, 06810
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

MannKind Headlines

No Headlines